Skip to content

Microwave Ablation of Resectable Liver Tumors

Microwave Ablation of Resectable Liver Tumors

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00892255
Enrollment
0
Registered
2009-05-04
Start date
2009-04-30
Completion date
2009-04-30
Last updated
2021-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma, Liver Cancer

Keywords

Liver cancer, Tumors

Brief summary

The purpose of this protocol is to pathologically evaluate the destruction by microwave ablation of primary and metastatic liver tumors. The primary aim is to measure tissue destruction with the MedWaves Microwave Ablation/ Coagulation Ablation System.

Detailed description

Minimally invasive surgical alternatives are becoming more attractive for the treatment of malignancy.The goal is to reduce morbidity and mortality and increase the ability to treat patients in the outpatient setting. Image-guided ablation is becoming an attractive alternative because of its relative low cost, its ability to provide large regions of coagulative necrosis in a controlled fashion, and its relatively low toxicity. Although image-guided ablative techniques have been extensively investigated for the treatment of liver tumors, there has been limited experience with microwave ablation (MWA) in the liver. This study will evaluate the treatment effect of MWA in liver tumors. Patients undergoing planned surgical removal of liver tumors will have the tumors intra-operatively treated with MWA. The histological changes will be evaluated upon removal of the specimen.

Interventions

DEVICEMicrowave Ablation

Tumor tissue from the liver is inter-operatively treated with the microwave ablation device to measure the destruction of tissue.

Sponsors

St. Joseph Hospital of Orange
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosis of primary or metastatic liver cancer for which surgery is planned * All participants need to be fully able to give informed consent

Exclusion criteria

* Mental or legal incompetence * Impaired decision-making capacity * Pregnant women may not participate

Design outcomes

Primary

MeasureTime frameDescription
Measure of the tissue destruction with the MedWaves Microwave Ablation/ Coagulation Ablation System30 DaysMeasure of the tissue destruction with the MedWaves Microwave Ablation/ Coagulation

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026